

Daniele Pastori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/649549/publications.pdf>

Version: 2024-02-01

277
papers

7,208
citations

61984

43
h-index

85541

71
g-index

286
all docs

286
docs citations

286
times ranked

9798
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2017, 153, 480-487.e1.	1.3	301
2	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes" A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	3.4	219
3	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. <i>Hepatology</i> , 2020, 72, 470-485.	7.3	203
4	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , 2020, 120, 949-956.	3.4	183
5	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , 2015, 7, 1325.	2.0	152
6	Oxidative stress and cardiovascular disease: new insights. <i>Kardiologia Polska</i> , 2018, 76, 713-722.	0.6	150
7	Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2. <i>Circulation</i> , 2012, 126, 92-103.	1.6	148
8	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	143
9	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13378.	3.4	141
10	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events" Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2324-2331.e4.	4.4	136
11	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1917-1925.	2.8	134
12	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. <i>Lancet, The</i> , 2022, 399, 1383-1390.	13.7	131
13	A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects. <i>Chest</i> , 2019, 155, 510-518.	0.8	124
14	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2015, 47, 4-11.	0.9	121
15	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 647-651.	1.6	110
16	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. <i>American Journal of Gastroenterology</i> , 2017, 112, 1832-1839.	0.4	109
17	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	105
18	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1083-1124.	5.4	92

#	ARTICLE	IF	CITATIONS
19	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. Mayo Clinic Proceedings, 2019, 94, 1261-1267.	3.0	89
20	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients, 2020, 12, 2762.	4.1	89
21	Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque. Scientific Reports, 2018, 8, 3598.	3.3	88
22	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. Haematologica, 2020, 105, 562-572.	3.5	81
23	Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. Nutrition and Diabetes, 2015, 5, e172-e172.	3.2	74
24	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. British Journal of Clinical Pharmacology, 2017, 83, 88-95.	2.4	74
25	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. International Journal of Cardiology, 2018, 264, 58-63.	1.7	69
26	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. American Journal of Medicine, 2019, 132, 856-861.	1.5	67
27	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. Sleep Medicine, 2018, 43, 66-70.	1.6	66
28	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. Atherosclerosis, 2014, 235, 649-658.	0.8	62
29	Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8341.	3.3	61
30	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circulation Research, 2020, 127, 400-401.	4.5	60
31	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. Chest, 2015, 147, 1644-1650.	0.8	59
32	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	3.3	59
33	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. International Journal of Cardiology, 2015, 201, 513-516.	1.7	57
34	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 1455-1462.	2.8	57
35	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. Thrombosis and Haemostasis, 2017, 117, 1558-1570.	3.4	56
36	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 866-875.	3.4	52

#	ARTICLE	IF	CITATIONS
37	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , 2015, 2, 750-754.	6.1	51
38	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	51
39	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 617-624.	3.4	50
40	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists. <i>Medicine (United States)</i> , 2016, 95, e2895.	1.0	50
41	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 682-687.	5.4	49
42	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. <i>Europace</i> , 2014, 16, 1107-1116.	1.7	47
43	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 107-114.	3.3	45
44	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. <i>Scientific Reports</i> , 2017, 7, 15756.	3.3	45
45	Under-prescription of statins in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 161-167.	2.6	45
46	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , 2021, 127, 2122-2129.	4.1	45
47	Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?. <i>Internal and Emergency Medicine</i> , 2014, 9, 123-131.	2.0	41
48	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , 2016, 11, 199-204.	2.0	41
49	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605,771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f11-f19.	3.0	40
50	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715878.	2.4	39
51	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015, 70, 961-966.	5.6	38
52	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , 2018, 261, 92-98.	1.7	37
53	Vitamin E Serum Levels and Bleeding Risk in Patients Receiving Oral Anticoagulant Therapy: a Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000364.	3.7	36
54	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016, 8, 275-283.	1.5	36

#	ARTICLE	IF	CITATIONS
55	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2018, 7, 378.	2.4	36
56	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. <i>Clinical and Translational Science</i> , 2020, 13, 1071-1076.	3.1	36
57	Anoxia-Reoxygenation Enhances Platelet Thromboxane A ₂ Production via Reactive Oxygen Species-Generated NOX2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1766-1771.	2.4	35
58	Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2020, 109, 96-102.	3.3	35
59	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , 2020, 126, 1415-1442.	4.5	35
60	The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors. <i>Antioxidants</i> , 2021, 10, 146.	5.1	35
61	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	1.7	35
62	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 142-148.	4.9	34
63	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 180, 1-5.	1.7	33
64	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 1732.	4.1	33
65	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2904-2911.	2.6	33
66	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. <i>Heart</i> , 2012, 98, 1063-1066.	2.9	32
67	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 50-55.	1.9	32
68	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , 2021, 50, 245-261.	1.7	32
69	Severity of OSAS, CPAP and cardiovascular events: A follow-up study. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12908.	3.4	31
70	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2019, 16, 91-98.	3.2	31
71	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 856-863.	3.4	30
72	Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00123.	2.5	30

#	ARTICLE	IF	CITATIONS
73	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	2.0	29
74	Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879356.	3.2	29
75	Off-label use of ceftaroline fosamil: A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 562-571.	2.5	29
76	Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 2018, 107, 772-777.	3.3	28
77	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 519-525.	5.8	28
78	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , 2020, 9, 296.	5.1	28
79	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 441-451.	2.4	28
80	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 490-497.e1.	2.7	26
81	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 890-895.	2.6	26
82	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7193.	4.1	26
83	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. <i>American Journal of Hematology</i> , 2012, 87, 384-387.	4.1	25
84	Is NOX2 Upregulation Implicated in Myocardial Injury in Patients with Pneumonia?. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 2949-2954.	5.4	25
85	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e113.	2.5	25
86	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , 2015, 34, 899-903.	5.0	25
87	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. <i>European Journal of Nutrition</i> , 2019, 58, 843-851.	3.9	25
88	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 28-36.	3.1	25
89	Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilation in Patients With Cardiometabolic Risk Factors. <i>American Journal of Cardiology</i> , 2015, 115, 1402-1406.	1.6	24
90	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015, 179, 139-143.	1.7	24

#	ARTICLE	IF	CITATIONS
91	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2455-2463.	2.4	24
92	Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2014, 7, 1112.	0.5	24
93	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. <i>European Journal of Internal Medicine</i> , 2014, 25, 566-570.	2.2	23
94	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e012596.	3.7	23
95	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2019, 25, 4172-4180.	3.3	23
96	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016, 113, 484-489.	7.1	22
97	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017, 231, 143-149.	1.7	22
98	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , 2020, 4, 1034-1040.	4.3	22
99	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2021, 96, 658-665.	3.0	22
100	Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. <i>Nutrients</i> , 2022, 14, 1127.	4.1	22
101	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015, 5, e008026-e008026.	1.9	21
102	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 255, 69-73.	1.7	21
103	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , 2020, 15, 135-143.	2.0	21
104	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , 2020, 8, 625.	3.2	21
105	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	2.0	21
106	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021, 85, 80-85.	2.2	21
107	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , 2021, 165, 105418.	7.1	21
108	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	1.6	20

#	ARTICLE	IF	CITATIONS
109	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 561-576.	2.6	20
110	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 698008.	3.5	20
111	Total Adiponectin Is Inversely Associated with Platelet Activation and CHA ₂ DS ₂ -VASc Score in Anticoagulated Patients with Atrial Fibrillation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	3.0	19
112	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017, 262, 179-184.	0.8	19
113	Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2019, 292, 126-130.	1.7	19
114	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 508-515.	2.4	19
115	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28014-28021.	4.1	18
116	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2018, 54, 34-39.	2.2	18
117	SARS-CoV-2 and myocardial injury: a role for Nox2?. <i>Internal and Emergency Medicine</i> , 2020, 15, 755-758.	2.0	18
118	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , 2016, 7, 39143-39147.	1.8	18
119	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , 2015, 70, 651-658.	3.3	17
120	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. <i>Internal and Emergency Medicine</i> , 2017, 12, 1159-1165.	2.0	16
121	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <i>Biochemical Pharmacology</i> , 2019, 163, 111-118.	4.4	16
122	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 355-360.	2.1	16
123	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 751-755.	5.4	15
124	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2016, 36, 74-80.	2.2	15
125	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2301-2308.	3.9	15
126	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , 2019, 108, 1034-1041.	3.3	15

#	ARTICLE	IF	CITATIONS
127	Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1291-1298.	3.4	15
128	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , 2020, 152, 355-362.	2.9	15
129	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , 2016, 244, 48-50.	0.8	14
130	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020, 190, 588-593.	2.5	14
131	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13771.	1.7	14
132	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. <i>Heart Failure Reviews</i> , 2023, 28, 667-681.	3.9	14
133	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , 2015, 17, 1223-1228.	1.7	13
134	Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation. <i>Nutrition</i> , 2018, 55-56, 36-40.	2.4	13
135	Dementia and Atrial Fibrillation: A Dangerous Combination for Ischemic Stroke and Mortality. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1129-1132.	2.6	13
136	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , 2018, 274, 29-34.	0.8	13
137	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 200, 32-36.	2.7	13
138	Aging and Adherence to the Mediterranean Diet: Relationship with Cardiometabolic Disorders and Polypharmacy. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 73-81.	3.3	13
139	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , 2019, 183, 28-32.	1.7	13
140	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4120.	4.1	13
141	Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study. <i>Nutrients</i> , 2021, 13, 2811.	4.1	13
142	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. <i>Europace</i> , 2022, 24, 375-383.	1.7	13
143	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 3241-3247.	1.7	12
144	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , 2018, 50, 511-518.	3.8	12

#	ARTICLE	IF	CITATIONS
145	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , 2019, 289, 195-200.	0.8	12
146	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , 2021, 26, 1425.	3.8	12
147	Undifferentiated Connective Tissue Disease - An Unsolved Problem: Revision of Literature and Case Studies. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 271-278.	2.1	11
148	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2016, 223, 619-624.	1.7	11
149	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2019, 124, 723-728.	1.6	11
150	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 513-520.	3.0	11
151	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. <i>American Heart Journal</i> , 2017, 189, 120-127.	2.7	10
152	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018, 50, 288-302.	3.8	10
153	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00116.	2.5	10
154	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021, 327, 176-182.	1.7	10
155	Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the C ₂ HEST Score: The West Birmingham Atrial Fibrillation Project. <i>Journal of the American Heart Association</i> , 2021, 10, e017519.	3.7	10
156	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8993.	2.6	10
157	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis. <i>Thrombosis Journal</i> , 2021, 19, 102.	2.1	10
158	Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1260.	4.1	10
159	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018, 132, 149-159.	7.1	9
160	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. <i>Journal of the American Heart Association</i> , 2018, 7, e009509.	3.7	9
161	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	2.0	9
162	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3180.	2.4	9

#	ARTICLE	IF	CITATIONS
163	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. Scientific Reports, 2017, 7, 3797.	3.3	8
164	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and Haemostasis, 2019, 119, 576-585.	3.4	8
165	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. Frontiers in Cardiovascular Medicine, 2019, 6, 17.	2.4	8
166	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962094579.	1.7	8
167	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO-AF study. International Journal of Cancer, 2020, 147, 3424-3430.	5.1	8
168	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. Frontiers in Pharmacology, 2021, 12, 695961.	3.5	8
169	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. Frontiers in Cardiovascular Medicine, 2021, 8, 779503.	2.4	8
170	Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process. Antioxidants, 2021, 10, 1790.	5.1	8
171	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. Thrombosis Research, 2022, 209, 69-74.	1.7	8
172	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infectious Diseases, 2011, 11, 341.	2.9	7
173	Immunomodulatory Effects of Intravenous Immunoglobulins (IVIGs) in HIV-1 Disease: A Systematic Review. International Reviews of Immunology, 2011, 30, 44-66.	3.3	7
174	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. Progress in Cardiovascular Diseases, 2018, 60, 537-541.	3.1	7
175	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. International Journal of Molecular Sciences, 2018, 19, 603.	4.1	7
176	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. Current Problems in Cardiology, 2021, 46, 100410.	2.4	7
177	Anticoagulation in patients with advanced liver disease: an open issue. Internal and Emergency Medicine, 2021, 16, 61-71.	2.0	7
178	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. Digestive and Liver Disease, 2021, 53, 383-384.	0.9	7
179	Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department. Internal and Emergency Medicine, 2022, 17, 1777-1784.	2.0	7
180	Optical coherence tomography-derived lipid core burden index and clinical outcomes: results from the CLIMA registry. European Heart Journal Cardiovascular Imaging, 0, .	1.2	7

#	ARTICLE	IF	CITATIONS
181	Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. American Journal of Cardiology, 2020, 132, 72-78.	1.6	6
182	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. Clinical Gastroenterology and Hepatology, 2021, 19, 2683-2684.	4.4	6
183	Acute atrial ischemia associates with early but not late new-onset atrial fibrillation in STEMI patients treated with primary PCI: relationship with in-hospital outcomes. Journal of Cardiology, 2021, 78, 368-374.	1.9	6
184	Pentraxin 3 “A Link Between Obesity, Inflammation and Vascular Disease?”. Circulation Journal, 2016, 80, 327-328.	1.6	5
185	Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants. American Heart Journal, 2018, 198, 166-168.	2.7	5
186	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data in Brief, 2018, 17, 830-836.	1.0	5
187	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2021, 141, 1-6.	1.6	5
188	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Internal and Emergency Medicine, 2021, 16, 2063-2068.	2.0	5
189	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. Free Radical Biology and Medicine, 2021, 168, 1-5.	2.9	5
190	Isoprostanes in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102821.	5.8	5
191	Time to hospitalisation, CT pulmonary involvement and in-hospital death in COVID-19 patients in an Emergency Medicine Unit. International Journal of Clinical Practice, 2021, 75, e14426.	1.7	5
192	The challenge of cardiovascular prevention in NAFLD. The Lancet Gastroenterology and Hepatology, 2021, 6, 877-878.	8.1	5
193	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.. Current Pharmaceutical Design, 2015, 21, 5945-5950.	1.9	5
194	Thrombosis in pre- and post-vaccination phase of COVID-19. European Heart Journal Supplements, 2021, 23, E184-E188.	0.1	5
195	Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 720.	3.2	5
196	Aging-Related Decline of Autophagy in Patients with Atrial Fibrillation “A Post Hoc Analysis of the ATHERO-AF Study. Antioxidants, 2022, 11, 698.	5.1	5
197	Direct oral anticoagulant reversal: how, when and issues faced. Expert Review of Hematology, 2017, 10, 1005-1022.	2.2	4
198	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	1.6	4

#	ARTICLE	IF	CITATIONS
199	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 786-790.	5.4	4
200	Clinical and pharmacological characteristics of elderly patients admitted for bleeding: impact on in-hospital mortality. <i>Annals of Medicine</i> , 2020, 52, 413-422.	3.8	4
201	Antiphospholipid antibodies in <scp>endâ€stage</scp> renal disease: A systematic review and <scp>metaâ€analysis</scp>. <i>Hemodialysis International</i> , 2020, 24, 383-396.	0.9	4
202	The Atrial Fibrillation Better Care (ABC) pathway in atrial fibrillation: a systematic review and meta-analysis of 285,000 patients. <i>Europace</i> , 2021, 23, .	1.7	4
203	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. <i>HIV Medicine</i> , 2021, 22, 434-444.	2.2	4
204	Clinical Phenotypes of Atrial Fibrillation and Mortality Riskâ€”A Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , 2022, 12, 785.	2.5	4
205	Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals. <i>Aids</i> , 2009, 23, 2233-2234.	2.2	3
206	Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. <i>AIDS Research and Therapy</i> , 2011, 8, 9.	1.7	3
207	Statins and nonâ€alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1787-1787.	3.9	3
208	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008477.	4.8	3
209	Sex-Related Differences in the Association between Metabolic Syndrome and Gallstone Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1958.	2.6	3
210	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients. <i>Italian Journal of Emergency Medicine</i> , 2021, 10, .	0.1	3
211	Prevention and management of type II diabetes chronic complications: the role of polyphenols (Mini-Review). <i>Current Medicinal Chemistry</i> , 2021, 28, .	2.4	3
212	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Journal of Autoimmunity</i> , 2022, 129, 102832.	6.5	3
213	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , 2015, 26, e31-e33.	2.2	2
214	Reply. <i>Gastroenterology</i> , 2018, 154, 761-762.e1.	1.3	2
215	Enhanced urinary excretion of thromboxane B2 in non-alcoholic fatty liver disease. Implication for antiplatelet treatment. <i>Atherosclerosis</i> , 2018, 275, e65-e66.	0.8	2
216	The platelets behaviour in non-alcoholic fatty liver disease. A potential role for antiplatelets drugs?. <i>European Heart Journal</i> , 2020, 41, .	2.2	2

#	ARTICLE	IF	CITATIONS
217	P1049 : Lysosomal Acid Lipase activity in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2015, 62, S742.	3.7	1
218	Visceral fat evaluated by ultrasound is associated with insulin resistance and liver damage in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, e32.	2.6	1
219	Assessment of blood hydrogen peroxide break-down activity (HBA) in healthy subjects and in patients with atrial fibrillation: relation to cardiovascular events. Atherosclerosis, 2018, 275, e252-e253.	0.8	1
220	Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?. Thrombosis and Haemostasis, 2018, 118, 1847-1849.	3.4	1
221	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. Diabetic Medicine, 2018, 35, 1134-1135.	2.3	1
222	Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Internal and Emergency Medicine, 2019, 14, 1199-1201.	2.0	1
223	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. International Journal of Cardiology, 2021, 322, 245-249.	1.7	1
224	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. International Journal of Clinical Practice, 2021, 75, e14064.	1.7	1
225	Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Europace, 2021, 23, .	1.7	1
226	Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer. European Heart Journal, 2021, 42, .	2.2	1
227	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. European Journal of Case Reports in Internal Medicine, 2019, 6, 1.	0.4	1
228	REPLY to "Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome". Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	1
229	Vitamin e serum level, a new tool to stratify bleeding risk in patients receiving oral anticoagulant therapy. European Heart Journal, 2013, 34, P534-P534.	2.2	0
230	Vitamin e serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. European Heart Journal, 2013, 34, P5606-P5606.	2.2	0
231	P848 SERUM CYTOKERATIN-18 IS ASSOCIATED WITH OXIDATIVE STRESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S354.	3.7	0
232	P825 NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH REDUCED SERUM CHOLESTEROL-ADJUSTED VITAMIN E LEVELS. Journal of Hepatology, 2014, 60, S346.	3.7	0
233	P812 NOX2-GENERATED OXIDATIVE STRESS IS INCREASED IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE INDEPENDENTLY FROM METABOLIC SYNDROME. Journal of Hepatology, 2014, 60, S341.	3.7	0
234	NOX2-generated oxidative stress is increased in patients with non-alcoholic fatty liver disease independently from metabolic syndrome. Digestive and Liver Disease, 2014, 46, e27.	0.9	0

#	ARTICLE	IF	CITATIONS
235	Response to “Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality” International Journal of Cardiology, 2015, 189, 247-248.	1.7	0
236	Obstructive Sleep Apnea and the Metabolic Syndrome. , 2015, , 177-184.		0
237	Reply to “The relation between flow mediated dilation and atrial fibrillation” by S. Balta. International Journal of Cardiology, 2015, 201, 225-226.	1.7	0
238	Short-term modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F ₂ in HIV-1 patients on abacavir-based therapies. HIV Medicine, 2016, 17, 774-777.	2.2	0
239	Spleen Dimensions Evaluated by Ultrasound are Inversely Associated with Lysosomal Acid Lipase Activity in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S489.	3.7	0
240	Reply to: “Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke” International Journal of Cardiology, 2016, 202, 934-935.	1.7	0
241	ADHERENCE TO MEDITERRANEAN DIET AND NON ALCOHOLIC FATTY LIVER DISEASE: IMPACT ON METABOLIC PROFILE. Journal of the American College of Cardiology, 2017, 69, 1868.	2.8	0
242	Reply to: “Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality” Atherosclerosis, 2017, 256, 148-149.	0.8	0
243	Reply. Journal of the American College of Cardiology, 2018, 71, 706-707.	2.8	0
244	Response to Duret et al.. American Journal of Gastroenterology, 2018, 113, 775-776.	0.4	0
245	Progressive reduction of blood lysosomal acid lipase activity according to stage of adult chronic liver disease and altered enzymatic cellular distribution in cirrhosis. Digestive and Liver Disease, 2018, 50, 37.	0.9	0
246	P1882 Relationship between inflammation and atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. European Heart Journal, 2018, 39, .	2.2	0
247	Mechanisms of digoxin-related platelet activation in atrial fibrillation patients: In vivo and in vitro study. Atherosclerosis, 2018, 275, e95-e96.	0.8	0
248	Increased gut permeability is associated with oxidative stress in patients with NAFLD. Journal of Hepatology, 2018, 68, S821-S822.	3.7	0
249	P3472 Modifications of renal function in atrial fibrillation patients treated with different oral anticoagulants: a multicentre cohort study. European Heart Journal, 2019, 40, .	2.2	0
250	Anticoagulants in Atrial Fibrillation and Liver Disease. Journal of the American College of Cardiology, 2019, 74, 2436.	2.8	0
251	Lysosomal Acid Lipase Activity And Hepatic Fibrosis In Non-Alcoholic Fatty Liver Disease. Atherosclerosis, 2019, 287, e122.	0.8	0
252	P5454 PCSK9 as a predictor of cardiovascular events in atrial fibrillation: role of platelet activation. European Heart Journal, 2019, 40, .	2.2	0

#	ARTICLE	IF	CITATIONS
253	Statins reduce major adverse limb events and mortality in patients with peripheral artery disease. <i>Atherosclerosis</i> , 2020, 315, e53.	0.8	0
254	Impaired HDL cholesterol efflux capacity in subjects with metabolically- but not genetically- driven non-alcoholic fatty liver disease (NAFLD). <i>Atherosclerosis</i> , 2020, 315, e155.	0.8	0
255	Liver fibrosis and cardiovascular events in non-alcoholic fatty liver disease. The prospective cohort plinio study. <i>Atherosclerosis</i> , 2020, 315, e48.	0.8	0
256	Lipid profile, oxidative stress and platelets activation after albumin infusion in congenital analbuminemia. <i>Atherosclerosis</i> , 2020, 315, e84.	0.8	0
257	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. <i>Thrombosis and Haemostasis</i> , 2021, 121, 700-702.	3.4	0
258	Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device. <i>Europace</i> , 2021, 23, .	1.7	0
259	Acute atrial ischemia associates with early but not late new-onset atrial fibrillation in STEMI patients treated with primary PCI: relationship with in-hospital outcomes. <i>Europace</i> , 2021, 23, .	1.7	0
260	Comparison of bleeding risk scores in patients with atrial fibrillation and cancer. <i>Europace</i> , 2021, 23, .	1.7	0
261	Commentary on “Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial” • <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 699-701.	1.5	0
262	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronisation devices. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
263	Early vs late new-onset atrial fibrillation in STEMI patients: pathophysiological mechanisms and relationship with in-hospital outcomes. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
264	Abstract 16732: Urinary 11-Dehydro-Thromboxane B2 is Associated With Vascular and Non-Vascular Events in Atrial Fibrillation Patients. <i>Circulation</i> , 2014, 130, .	1.6	0
265	Integrated care management of patients with atrial fibrillation “far from optimal. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 176-178.	0.4	0
266	High D-dimer levels in patients with Takotsubo syndrome: 2.5 years follow-up. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
267	Effect of prophylactic and therapeutic low molecular weight heparins on mortality in 15,704 COVID-19 patients. A systematic review and a meta-analysis. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
268	Paroxysmal nocturnal hemoglobinuria and cardio-respiratory system: new pathophysiological evidences. , 2020, , .		0
269	Clinical phenotypes of atrial fibrillation and risk of mortality: a cluster analysis. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
270	Incidence, type and prediction of death in anticoagulated patients with atrial fibrillation: a post-hoc analysis from the SPORTIF trials. <i>European Heart Journal</i> , 2020, 41, .	2.2	0

#	ARTICLE	IF	CITATIONS
271	The Atrial fibrillation Better Care (ABC) pathway is associated to a lower incidence of cardiac complications in patients with atrial fibrillation: a report from the ATHERO-AF study. European Heart Journal, 2020, 41, .	2.2	0
272	Risk of cardiovascular events in patients with atrial fibrillation and cancer. Data from the ATHERO-AF cohort. European Heart Journal, 2020, 41, .	2.2	0
273	Identifying at-risk subjects for sustained atrial high-rate episodes using the C2HEST score: the West Birmingham AF project. European Heart Journal, 2020, 41, .	2.2	0
274	Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study. European Heart Journal, 2021, 42, .	2.2	0
275	A Meta-Analysis of Plasma Homocysteine in Buerger's Disease. Thrombosis and Haemostasis, 2022, , .	3.4	0
276	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry. Platelets, 2022, , 1-6.	2.3	0
277	231 In-hospital outcomes following an acute coronary syndrome in patients with liver fibrosis: results from the real-world observational registry of acute coronary syndromes (REALE-ACS). European Heart Journal Supplements, 2021, 23, .	0.1	0